Treats relapsing forms of multiple sclerosis (MS). ANDA 210414, held by Prinston. Dimethyl Fumarate.
As of Nov 16, 2026, ANDA 210414 (Dimethyl Fumarate), held by Prinston, was first approved by FDA on Oct 18, 2022, with 4 approved supplements and 0 published complete response letters.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2022 | Original application | Approved | None posted |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Nov 4, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 4, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 4, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 4, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 18, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters